XBI · State Street(R) SPDR(R) S&P(R) Biotech ETF
XBI tracks the SPDR S&P Biotech and returned +64.0% over the past year.
Key facts
Its ten largest equity positions
| Holding | Weight | |
|---|---|---|
| Apogee Therapeutics Inc | 1.49% | |
| Moderna Inc | 1.41% | |
| Twist Bioscience Corp | 1.41% | |
| Oruka Therapeutics Inc | 1.38% | |
| Kymera Therapeutics Inc | 1.36% | |
| Viking Therapeutics Inc | 1.31% | |
| Praxis Precision Medicines Inc | 1.29% | |
| Erasca Inc | 1.27% | |
| Revolution Medicines Inc | 1.21% | |
| Rhythm Pharmaceuticals Inc | 1.20% |
Compare XBI
Also against BIL, BINC, BITO, BND, BNDX, BOND, BOXX, BSV, BWET, CGBL, CGDV, CGGR, COWZ, CTA, DBMF, DFUS, DGRO, DGRW, DIA, DVY, DYNF, EDV, EEM, EFA, EMB, EMXC, EWJ, EWT, EWY, EWZ, EZU, FBCG, FDVV, FENI, FLKR, FNDX, FTEC, FXI, GARP, GDX, GLD, GLDM, GOVT, GRNY, HDV, HGER, HYG, HYMB, IALT, IAU, IBB, IDEV, IEF, IEFA, IEI, IEMG, IGIB, IGM, IGSB, IJH, IJR, IJS, IJT, ILF, INDA, ITOT, IUSB, IVV, IWB, IWC, IWD, IWF, IWM, IWO, IXUS, IYE, IYR, IYW, JAAA, JNK, KRE, LQD, LYTE, MAGS, MBB, MDY, MGK, MINT, MOAT, MTUM, MUB, NOBL, ONEQ, PDBC, PFF, PULS, PVAL, QQQ, QQQM, QUAL, RDVY, REMX, RSP, SCHB, SCHD, SCHF, SCHG, SCHH, SCHP, SCHX, SDY, SGOV, SHV, SHY, SIVR, SLV, SPHD, SPHQ, SPLG, SPMO, SPSB, SPY, SPYD, SPYG, TIP, TLT, URTH, USFR, USHY, USMV, USO, VB, VBIL, VBK, VBR, VCIT, VCLT, VCSH, VDC, VDE, VEA, VEU, VGIT, VGK, VGLT, VGSH, VGT, VHT, VIG, VLUE, VNQ, VO, VOE, VONG, VOO, VOOG, VOX, VPL, VPU, VT, VTEB, VTI, VTIP, VTV, VTWO, VUG, VUSB, VWO, VXF, VXUS, VYM, VYMI, XHB, XLB, XLC, XLE, XLF, XLG, XLI, XLK, XLP, XLRE, XLU, XLV, XLY, XOP, XOVR, XRT.
Period by period
| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
|---|---|---|---|---|
| 3 months | +16.9% | +3.3% | +13.6 pts | +17.6 pts |
| 6 months | +28.3% | +16.0% | +12.3 pts | +7.6 pts |
| 1 year | +64.0% | +17.5% | +46.5 pts | +41.0 pts |
| 3 years | +98.6% | +77.9% | +20.7 pts | +3.5 pts |
| Since listing | +793.4% | +804.4% | −11.0 pts | −880.6 pts |
In plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
| What it tracks | SPDR S&P Biotech |
|---|---|
| Fund type | Index equity fund |
| Expense ratio (485BPOS XBRL, Oct 24, 2025) | 0.35% |
| Price | $156.20 |
| Listed since | Jan 4, 2010 |
| Net assets (SEC filing, whole fund, as filed for Jun 30, 2026) | $10.7bn |
| Below its high (ETFIQ) | −9.6% |
| Holdings | 150 |
| Top ten weight | 13.3% |
| Holdings as of (SEC N-PORT) | Jun 30, 2026 |
| Already in the S&P 500, by weight (ETFIQ) | 8.5% |
| Active share vs the S&P 500 (ETFIQ) | 98.4% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 6.0% |
Questions people ask
- How has XBI performed?
- Over the year to Sep 11, 2026, XBI returned +64.0% with distributions reinvested, against +17.5% for the S&P 500. Over three years the figure is +98.6%.
- What does XBI cost?
- The prospectus expense ratio is 0.35% a year.
- What does XBI hold?
- 150 positions as filed for Jun 30, 2026, with the top ten at 13.3% of the fund. 8% of its weight is in stocks the S&P 500 also holds.
- How far is XBI below its high?
- 9.6% below its high of Feb 8, 2021, measured on the reinvested series to Sep 11, 2026.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Cite this page. ETFIQ, XBI, core index fund, data as of Sep 11, 2026. https://etfiq.com/funds/XBI Free to use with attribution; the underlying files are at Open data.
ETFIQ covers leveraged and inverse, thematic, buffer, option-income, core index and spot crypto ETFs. This fund is here because the other funds here are measured against it and portfolios hold it. ETFIQ is an independent publisher and makes no recommendations. Standards and sources